Antidepressant sertraline works ‘by reducing anxiety symptoms first’
September 20, 2019Medical Communications, Research and Development antidepressant, sertraline
Researchers at University College London have found that a commonly prescribed antidepressant, sertraline, works in unexpected ways, first relieving users …
Novo’s Tresiba lowers hypoglycaemia risk compared to insulin glargine in type 2 diabetes
September 20, 2019Medical Communications, Research and Development Novo Nordisk, Tresiba, diabetes, pharma
Novo Nordisk has unveiled new data for Tresiba (insulin degludec) at the 55th Annual Meeting of the European Association for …
Biogen to start new Spinraza trial to preserve market share
September 20, 2019Medical Communications, Research and Development
Biogen is planning a new trial of $1.7billion-a-year Spinraza to investigate much higher doses in spinal muscular atrophy (SMA) and …
Lundbeck and Takeda’s depression drug approved in Japan
September 20, 2019Medical Communications, Sales and Marketing Japan, Lundbeck, Takeda, major depressive disorder, pharma
Takeda and Lundbeck have announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has chosen to authorise their drug …
Almost half of all cancer drug trials show bias and exaggeration
September 19, 2019Research and Development BMJ, Cancer, cancer drug trials
New research on clinical trials between 2014 and 2016 raise “serious concerns about low standards” as over the three year …
Sanofi’s Troujeo beats insulin degludec in head-to-head study in type 2 diabetes
September 19, 2019Research and Development Sanofi, Troujeo, diabetes, insulin degludec, pharma
Sanofi took the opportunity at the 55th annual European Association for the Study of Diabetes to present new data from …
British baby’s death not caused by Zolgensma says Novartis
September 19, 2019Research and Development AveXis, Novartis, Zolgensma, spinal muscular atrophy
Swiss drugmaker Novartis have stated that a British baby’s death this year after getting Novartis’ gene therapy Zolgensma, was not …
FDA expands Janssen’s Erleada label to cover metastatic castration-sensitive prostate cancer
September 19, 2019Sales and Marketing Cancer, Erleada, FDA, Janssen, pharma, prostate cancer
Janssen has announced that the FDA has expanded the label of its androgen receptor inhibitor Erleada (apalutamide) to include the …
Poor diabetes control costing NHS £3bn in avoidable treatment
September 19, 2019Business Services, Sales and Marketing
Findings being presented at this year’s European Association for the Study of Diabetes have shown that the NHS is losing …
NICE recommends Takeda’s Takhzyro for NHS use to prevent hereditary angioedema attacks
September 18, 2019Research and Development, Sales and Marketing NHS, NICE, Takeda, Takhzyro, pharma
UK drug watchdog NICE has announced its final draft guidance recommending Takeda’s subcutaneous injection Takhzyro (Lanadelumab) for use on the …
US, Canada and Australia simultaneously fast-track Keytruda/Lenvima combo for endometrial cancer
September 18, 2019Research and Development, Sales and Marketing Australian Therapeutic Goods Administration, Cancer, FDA, Health Canada, Lenvima, keytruda, pharma
The FDA has acted under a new initiative in collaboration with the Australian Therapeutic Goods Administration (TGA) and Health Canada, …
New agreement gives AstraZeneca full responsibility for Linzess in China
September 18, 2019Research and Development AstraZeneca, IBS-C, Linzess
AstraZeneca has amended its collaboration agreement with Ironwood Pharmaceuticals in China for Linzess (linaclotide), a first-in-class new treatment for patients …
Swiss biotech raises $16m for ‘undelivery mechanism’ in rare liver disease
September 18, 2019Research and Development liver disease, versantis
A new method from Swiss Biotech Versantis promises to give far better immediate care and offer a treatment for a …
Roche bags FDA Breakthrough for Gazyva in lupus nephritis
September 18, 2019Research and Development FDA, Gazyva, Roche, lupus nephritis
The US FDA has granted Breakthrough Therapy Designation to Gazyva (obinutuzumab) for adults with lupus nephritis. The win comes on …
New APPG report on access to cutting edge medicines
September 17, 2019Manufacturing and Production
A new report from the All-Party Parliamentary Groups (APPG) is urging the life science community to work together to speed …
UKRI Chief Executive Sir Mark Walport to step down in 2020
September 17, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing UKRI, appointment, pharma
Sir Mark Walport, Chief Executive of UK Research and Innovation (UKRI), the national funding agency responsible for science and research …
New experimental approach could stop common cold
September 17, 2019Manufacturing and Production, Research and Development
Scientists believe they may have found a way to stop the common cold as instead of attacking the virus directly, …
Acceleron terminates drug candidate following facioscapulohumeral muscular dystrophy failure
September 17, 2019Manufacturing and Production, Research and Development Acceleron, pharma, trial failure
Acceleron Pharma has seen its stock fall by almost 4% after it unveiled new Phase 2 data confirming that its …
Enlarged prostate drug may slow Parkinson’s disease
September 17, 2019Manufacturing and Production, Research and Development Parkinson's, terazosin
A surprising find has led researchers to see that a drug used to treat enlarged prostates may also work as …
Novartis’ Cosentyx has strong Phase 3 interim showing in axial spondyloarthritis
September 17, 2019Manufacturing and Production, Research and Development Cosentyx, Novartis, pharma
Novartis has highlighted new data from its ongoing Phase 3 trial into the efficacy and safety of itsinterleukin-17A inhibitor Cosentyx …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
